Moreira, A.; Erdmann, M.; Uslu, U.; Vass, V.; Schuler, G.; Schuler-Thurner, B.
Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA. Pharmaceutics 2020, 12, 210.
https://doi.org/10.3390/pharmaceutics12030210
AMA Style
Moreira A, Erdmann M, Uslu U, Vass V, Schuler G, Schuler-Thurner B.
Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA. Pharmaceutics. 2020; 12(3):210.
https://doi.org/10.3390/pharmaceutics12030210
Chicago/Turabian Style
Moreira, Alvaro, Michael Erdmann, Ugur Uslu, Verona Vass, Gerold Schuler, and Beatrice Schuler-Thurner.
2020. "Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA" Pharmaceutics 12, no. 3: 210.
https://doi.org/10.3390/pharmaceutics12030210
APA Style
Moreira, A., Erdmann, M., Uslu, U., Vass, V., Schuler, G., & Schuler-Thurner, B.
(2020). Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA. Pharmaceutics, 12(3), 210.
https://doi.org/10.3390/pharmaceutics12030210